Shanghai Fosun Pharmaceutical (600196.SH) plans to sell part of its equity in Gland Pharma through its holding subsidiary.

Shanghai Fosun Pharmaceutical (600196.SH) announced that on September 4, 2026, Indian time, its holding subsidiary Shanghai Fosun Pharmaceutical Singapore Company sold a total of 9.897 million shares of Gland Pharma (approximately 6.00% of the total number of Gland Pharma shares as of September 3, 2026) through block trading and centralized bidding, for a total consideration (before deducting transaction commissions and taxes) of 27.996 billion Indian Rupees (approximately 2.94 billion USD), with an average price (before deducting transaction commissions and taxes) of about 2,828.78 Indian Rupees per share, reflecting a discount of approximately 2.72% compared to the previous trading day's closing price (which was 2,907.90 Indian Rupees). The expected transfer time for the shares involved in this transaction is September 7, 2026, Indian time. Following the completion of this transaction, the group will still hold approximately 45.76% of Gland Pharma's equity (down from approximately 51.76% before the transaction) and will remain its controlling shareholder. Gland Pharma will continue to be a subsidiary within the scope of the groups consolidated financial statements. The proceeds from this transaction will primarily be used for the group's R&D investments, share buybacks, and repayment of interest-bearing debts. The proceeds from this sale will enhance the group's net assets; since this transaction involves the transfer of part of the equity of a holding subsidiary, the proceeds will not be included in the groups profit and loss statement as investment income.